Multivariate analysis of patients with medullary thyroid carcinoma: Prognostic significance and impact on treatment of clinical and pathologic variables

Cancer

Volumn 77, Issue 8, 1996, Pages 1556-1565

  Dottorini, Massimo E ^a   Assi, Agnese ^b   Sironi, Maria ^b   Sangalli, Gabriele ^a   Spreafico, Gianluigi ^b   Colombo, Luigia ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

^b General Hospital   (Italy)

Author keywords

immunohistochemistry; medullary carcinoma; risk factors; survival analysis; thyroid neoplasm; tumor markers

Indexed keywords

CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; THYROID MEDULLARY CARCINOMA; THYROID SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RABBITS; SURVIVAL ANALYSIS; THYROID NEOPLASMS;

EID: 0029916917     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960415)77:8<1556::AID-CNCR20>3.0.CO;2-Y     Document Type: Article

References (37)

1. Mathew CGP, Chin KS, Easton DF, Thorpe K, Carter C, Liou GI, et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 1987;328:527-8.
2. Mulligan LM, Kwok JBJ, Healy CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
3. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-6.
4. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367: 375-6.
5. Rougier P, Parmentier C, Laplanche A, Lefevre M, Travagli JP, Caillou B, et al. Medullary thyroid carcinoma: prognostic factors and treatment. Int J Radial Oncol Biol Phys 1983; 9:161-9.
6. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine 1984;63:319-42.
7. Gardet P, Rougier P, Laplanche A, Delisle MJ, Caillou B, Schlumberger M, et al. Cancers médullaires thyroïdiens. Facteurs pronostiques des formes sporadiques non associées. Implications thérapeutiques. Bull Cancer 1984;71:188-91.
8. Bergholm U, Adami HO, Bergström R, Johansson H, Lundell G, Telenius-Berg M, et al. Clinical characteristics in sporadic and familial medullary thyroid carcinoma. A nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer 1989;63:1196-204.
9. Bergholm U, Adami HO, Bergström R, Bäckdahl M, Åkerström G. Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristic as prognostic factors. Acta Chir Scand 1990; 156:37-46.
10. Gautvik KM. Medullary carcinoma of the thyroid. An update of diagnostic and prognostic factors. Scand J Clin Lab Invest 1991;51(Suppl 206):85-92.
11. Gharib H, McConahey WM, Tiegs RD, Bergstralh EJ, Goellner JR, Grant CS, et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 trough 1970. Mayo Clin Proc 1992;67:934-40.
12. Raue F, Kotzerke J, Reinwein D, Schröder S, Röher HD, Deckart H, et al. Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Invest 1993; 71:7-12.
13. Mendelsohn G. Markers as prognostic indicators in medullary thyroid carcinoma. Am J Clin Pathol 1991;95:297-8.
14. Saad MF, Ordonez NG, Guido JJ, Samaan NA. The prognostic value of calcitonin immunostaining in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1984;59:850-6.
15. Takami H, Bessho T, Kameya T, Mimura T, Ito K, Abe O, et al. Immunohistochemical study of medullary thyroid carcinoma: relationship of clinical features to prognostic factors in 36 patients. World J Surg 1988;12:572-9.
16. Bergholm U, Adami HO, Auer G, Bergström R, Bäckdahl M, Grimelius L, et al. Histopathologic characteristics and nuclear DNA content as prognostic factors in medullary thyroid carcinoma. A nationwide study in Sweden. Cancer 1989;64:135-42.
17. Pyke CM, Hay ID, Goellner JR, Bergstrahl EJ, van Heerden JA, Grant CS. Prognostic significance of calcitonin immunoreactivity, amyloid staining, and flow cytometric DNA measurements in medullary thyroid carcinoma. Surgery 1991; 110:964-71.
18. Pacini F, Basolo F, Elisei R, Fugazzola L, Cola A, Pinchera A. Medullary thyroid cancer: an immunohistochemical and humoral study using six separates antigenes. Am J Clin Pathol 1991;95:300-8.
19. Bose S, Kapila K, Verma K. Medullary carcinoma of the thyroid: a cytological, immunocytochemical and ultrastructural study. Diagn Cytopathol 1992;8:28-32.
20. Längle F, Soliman T, Neuhold N, Widhalm G, Niederle B, Roka S, et al. CD15 (LeuM1) immunoreactivity: prognostic factor for sporadic and hereditary medullary thyroid cancer? World J Surg 1994;18:583-7.
21. Neonakis E, Thomas GA, Davies HG, Wheeler MH, Williams ED. Expression of calcitonin and somatostatin peptide and mRNA in medullary thyroid carcinoma. World J Surg 1994;18:588-93.
22. World Health Organization. Histological typing of thyroid tumours, 1969-1981, 2nd ed. Berlin: Springer-Verlag 1988; 11-2.
23. Albores-Saavedra J, LiVolsi VA, Williams ED. Medullary carcinoma. Semin Diagn Pathol 1985;2:137-46.
24. Hermanek P, Sobin LH, editors. UICC TNM classification of malignant tumours, 4th ed. Berlin: Springer-Verlag, 1987.
25. Hellman DE, Kartchner M, Van Antwerp JD, Salmon SE, Patton DD, O'Mara R. Radioiodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1979;48:451-5.
26. Jensen MH, Davis RK, Derrick L. Thyroid cancer: a computer-assisted review of 5287 cases. Otolaryngol Head Neck Surg 1990;102:51-65.
27. Pelizzo MR, Bernante P, Piotto A, Toniato A, Girelli ME, Busnardo B, et al. The extent for surgery for thyroid medullary cancer. Tumori 1994;80:427-32.
28. Schröder S, Böcker W, Baisch H, Bürk CG, Arps H, Meiners I, et al. Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry and DNA content. Cancer 1988;61:806-16.
29. Busnardo B, Girelli ME, Pelizzo MR, Zorat PL, De Besi P, Eccher C. Different diagnostic significance of carcinoembryonic antigen vs calcitonin as tumor marker of medullary thyroid carcinoma. Acta Endocrinol 1983;102(Suppl 252): 57-8.
30. Hales M, Rosenau W, Okerlund MD, Galante M. Carcinoma of the thyroid with a mixed medullary and follicular pattern: Morphologic, immunohistochemical and clinical laboratory studies. Cancer 1982;50:1352-9.
31. van den Brekel MWM, Castelijns JA, Snow GB. Detection of lymph node metastases in the neck: radiologic criteria. Radiology 1994;192:617-8.
32. Barbot N, Calmettes C, Schuffenecker I, Saint-André JP, Franc B, Rohmer V, et al. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 1994;78:114-20.
33. Utiger RD. Medullary thyroid carcinoma, genes, and the prevention of cancer. N Engl J Med 1994;331:870-1.
34. Frilling A, Röher HD, Ponder BAJ. Presymptomatic screening for medullary thyroid carcinoma in patients with multiple endocrine neoplasia type 2A. World J Surg 1994;18:577-82.
35. Lips CJM, Landsvater RM, Höppener JWM, Geerdink RA, Blijham G, Jansen-Schillhorn van Veen JM, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331:828-35.
36. Ledger GA, Khosla S, Lindor NM, Thibodeau SN, Gharib H. Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II. Ann Intern Med 1995; 122:118-24.
37. Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire III WP. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine and dacarbazine. Cancer 1994;73:432-6.